This study introduces an innovative method for cancer immunotherapy utilizing genetically modified Escherichia coli Nissle 1917 (EcN) as an oral delivery mechanism for Glypican-1 (GPC1), a tumor-associated antigen. This evidence concerns the gene GPC1 and neoplasm.